Gastroesophageal Reflux Disease
📧 Sign up to get email alerts when something new happens for Gastroesophageal Reflux Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-06-07FDA Approved: DEXILANT — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Dexilant (dexlansoprazole) submitted by Takeda Pharmaceuticals America, expanding its labeling t…
-
FDA approval · 2018-06-07FDA Approved: ESOMEPRAZOLE STRONTIUM — Supplemental Application (R2 Pharma, LLC)
The FDA approved a supplemental application for Esomeprazole Strontium submitted by R2 Pharma, LLC under NDA202342.
-
FDA approval · 2018-06-07FDA Approved: OMEPRAZOLE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application (ANDA 203270) for Omeprazole from Aurobindo Pharma Limited, authorizing changes to an approved gener…
-
FDA approval · 2018-06-07FDA Approved: OMEPRAZOLE — Supplemental Application (Golden State Medical Supply, Inc.)
The FDA approved a supplemental application for the generic omeprazole from Golden State Medical Supply, Inc., authorizing changes to the ap…
-
FDA approval · 2018-06-07FDA Approved: OMEPRAZOLE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for the generic Omeprazole from Lannett Company, Inc., granting continued approval for this prod…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-05-31FDA Approved: OMEPRAZOLE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for omeprazole from Aurobindo Pharma Limited, authorizing their generic omeprazole product.
-
FDA approval · 2018-05-31FDA Approved: OMEPRAZOLE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's supplemental application for omeprazole, granting approval for the generic proton pump inhibitor product. This a…
-
FDA approval · 2018-05-31FDA Approved: OMEPRAZOLE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for omeprazole from Dr. Reddy's Laboratories Limited under the ANDA pathway.
-
CLINICAL_TRIALS trial_result · 2018-05-24Clinical Trial Update: A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects [Phase 1]
Phase 1 study comparing pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects has completed. The trial evaluated PK and t…
-
CLINICAL_TRIALS trial_result · 2018-05-15Clinical Trial Update: Esophageal Bolus Transit in Newborns With Gastroesophageal Reflux Disease
This clinical trial from the University of Turin reports on esophageal bolus transit in newborns with gastroesophageal reflux disease, and t…
-
CLINICAL_TRIALS trial_result · 2018-05-09Clinical Trial Update: Implementation of PPI Medication PGX Testing [Phase 4]
Phase 4 trial update on implementing pharmacogenomic testing for proton pump inhibitor (PPI) medication in gastroesophageal reflux disease.
-
CLINICAL_TRIALS trial_result · 2018-05-08Clinical Trial Update: 48 Hours Esophagal pH-monitoring With and Without Gaviscon [NA]
This completed clinical trial compared 48-hour esophageal pH monitoring with and without Gaviscon in patients with gastroesophageal reflux d…
-
CLINICAL_TRIALS trial_result · 2018-05-08Clinical Trial Update: Foreshortened Esophagus and Its Surgical Therapy
This clinical trial update reports on surgical therapy for foreshortened esophagus related to gastroesophageal reflux disease and hiatal her…
-
CLINICAL_TRIALS trial_result · 2018-05-04Clinical Trial Update: Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants [Phase 2, Phase 3]
A completed Phase 2/3 trial assessed the efficacy of Gaviscon-Advance in reducing post-supper acid pockets and night-time acid reflux in obe…
-
CLINICAL_TRIALS trial_result · 2018-05-01Clinical Trial Update: Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes [NA]
The document reports completion of a clinical trial evaluating the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) and its effect …
-
FDA approval · 2018-04-30FDA Approved: ESOMEPRAZOLE MAGNESIUM — Original Application (Sun Pharmaceutical Industries, Inc)
The FDA approved Sun Pharmaceutical's original application for Esomeprazole Magnesium, a proton pump inhibitor. It is used to treat gastroes…
-
FDA approval · 2018-04-24FDA Approved: RABEPRAZOLE SODIUM — Original Application (Ascend Laboratories, LLC)
FDA approved Rabeprazole sodium from Ascend Laboratories, LLC as an Original Application (ANDA 208644), authorizing a generic proton pump in…
-
FDA approval · 2018-04-13FDA Approved: PREVACID SOLUTAB — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for PREVACID Solutab (lansoprazole) from Takeda Pharmaceuticals America, Inc., indicating a regu…
-
CLINICAL_TRIALS research · 2018-04-13Clinical Trial Update: the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease [NA]
This entry describes a clinical trial updating factors related to bariatric surgery and its influence on gastroesophageal reflux disease. Th…
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment [Phase 3]
A Phase 3 trial comparing endoscopic fundoplication to proton pump inhibitors for gastroesophageal reflux disease was terminated.
-
CLINICAL_TRIALS research · 2018-03-21Clinical Trial Update: Gluten Related Disorders in Barrett's Esophagus [NA]
This clinical trial update reports a study on gluten-related disorders in Barrett's esophagus, sponsored by McMaster University; the current…
-
CLINICAL_TRIALS trial_result · 2018-02-26Clinical Trial Update: A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors [Phase 3]
Phase 3 randomized trial comparing medical and surgical treatments for GERD symptoms that do not respond to proton pump inhibitors; study co…
-
FDA approval · 2018-01-24FDA Approved: NEXIUM 24HR CLEARMINIS — Supplemental Application (Haleon US Holdings LLC)
FDA approved a supplemental application for NEXIUM 24HR CLEARMINIS (esomeprazole magnesium) submitted by Haleon US Holdings LLC. The action …
-
FDA approval · 2018-01-09FDA Approved: ACIPHEX — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for ACIPHEX (rabeprazole sodium) filed by Waylis Therapeutics LLC.
-
FDA approval · 2017-12-20FDA Approved: PROTONIX I.V. — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for PROTONIX I.V., approving its intravenous pantoprazole sodium formulation. This expands treat…